Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.

导出 OA

翻译打印收藏纠错

作者： Ana M,Hurtado ^[1] ; Gines,Luengo-Gil ^[1] ; Tzu H,Chen-Liang ^[1] ; Fabio,Amaral ^[2] ; Kiran,Batta ^[3] ; Laura,Palomo ^[4] ; Eva,Lumbreras ^[5] ; Bartlomiej,Przychodzen ^[6] ; Eva,Caparros ^[1] ; Marıa L,Amigo ^[1] ; Maria,Dıez-Campelo ^[5] ; Lurdes,Zamora ^[4] ; Eduardo J,Salido Fierrez ^[7] ; Jaroslaw P,Maciejewski ^[6] ; Francisco J,Ortuño ^[1] ; Vicente,Vicente ^[1] ; Marıa,Del Canizo ^[5] ; Francesc,Sole ^[4] ; Francisca,Ferrer-Marin ^[8] ; Daniel H,Wiseman ^[2] ; Andres,Jerez ^[1]

作者单位： Haematology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain. ^[1] Leukaemia Biology Laboratory, Cancer Research UK, Manchester Institute, University of Manchester, Manchester, UK. ^[2] Division of Cancer Sciences, Cancer Research UK, Manchester Institute, University of Manchester, Manchester, UK. ^[3] Josep Carreras Leukaemia- Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain. ^[4] Department of Haematology, Hospital Universitario de Salamanca, Salamanca, Spain. ^[5] Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, USA. ^[6] Department of Haematology, Virgen de la Arrixaca University Hospital, IMIB, Murcia, Spain. ^[7] Haematology Department, Hospital Morales Meseguer, IMIB-CIBERERUCAM, Murcia, Spain. ^[8]

关键词 CMML transcriptome cyclin dependent kinase inhibitor 1A (CDKN1A)excision repair cross-complementation group 1 (ERCC1)poly ADP-ribose polymerase 1 (PARP1)synthetic lethality